Fresh COVID Variant “Cicada” (BA.3.2) Spreads: What You Need to Know
Health officials are closely monitoring a newly emerging COVID-19 variant, BA.3.2, nicknamed “Cicada” due to its prolonged period of undetected circulation. The Centers for Disease Control and Prevention (CDC) recently published a report detailing its spread across the globe and within the United States.
Early Detection Through Advanced Surveillance
The CDC’s report highlights the effectiveness of traveler-based genomic surveillance and wastewater monitoring in detecting BA.3.2 early. The variant was first identified in a respiratory sample from South Africa in November 2024. Since then, it has been reported in 23 countries, with detections increasing since September 2025.
In the U.S., BA.3.2 has been found in nasal swabs from travelers, airplane wastewater, clinical samples from patients, and wastewater samples from 25 states. This multi-pronged approach to surveillance is proving crucial in tracking the virus’s evolution.
Genetic Divergence and Immune Evasion Potential
BA.3.2 is genetically distinct from previous variants, possessing approximately 70-75 substitutions and deletions in the spike protein gene sequence compared to JN.1 and LP.8.1. These changes raise concerns about the variant’s potential to evade immunity from prior infection or vaccination.
The CDC is actively analyzing these mutations to understand their impact on vaccine effectiveness and the severity of illness.
Global Spread and Current Prevalence
Globally, detections of BA.3.2 began to rise in September 2025. By February 11, 2026, the variant had been reported in 23 countries. In some European nations, like Denmark, Germany, and the Netherlands, BA.3.2 accounted for approximately 30% of sequenced cases.
Within the U.S., the prevalence of BA.3.2 among sequenced samples was 0.19% as of February 11, 2026, but has increased to 0.55% by March 12, 2026. The first U.S. Case identified through traveler screening occurred in June 2025, involving a person traveling from the Netherlands.
Sublineages and Ongoing Evolution
Phylogenetic analysis has revealed the emergence of two sublineages, BA.3.2.1 and BA.3.2.2, indicating the virus continues to evolve. Researchers are monitoring these sublineages to assess any changes in transmissibility or immune evasion.
Public Health Response and Future Outlook
While BA.3.2 has demonstrated immune evasion potential, current data does not suggest a more severe illness. All patients identified in the U.S. Have survived. The CDC emphasizes the importance of continued genomic surveillance to track the variant’s spread and inform public health strategies.
Sustained monitoring, combined with studies on vaccine and antiviral effectiveness, will be essential to guide future responses to SARS-CoV-2 variants.
FAQ About BA.3.2
What is the BA.3.2 variant? BA.3.2 is a newly identified SARS-CoV-2 variant with a high number of mutations in the spike protein.
Where was BA.3.2 first detected? It was first detected in South Africa in November 2024.
Is BA.3.2 more dangerous than other variants? Current data does not indicate increased severity, but its immune evasion potential is being closely monitored.
How is the CDC tracking BA.3.2? Through traveler-based genomic surveillance, wastewater monitoring, and national genomic surveillance programs.
Should I be concerned about BA.3.2? It’s key to stay informed and follow public health recommendations, but there is no need for undue alarm at this time.
Did you know? Wastewater surveillance can often detect new variants *before* they are identified in clinical cases, providing an early warning system for public health officials.
Pro Tip: Staying up-to-date with your COVID-19 vaccinations remains the best defense against severe illness, even with the emergence of new variants.
Stay informed about the latest developments in COVID-19 and other public health issues. Read the full CDC report here.
